Drugs & Therapy Perspectives

, Volume 30, Issue 9, pp 303–308

Dimethyl fumarate: a guide to its use in relapsing-remitting multiple sclerosis

  • Gillian M. Keating
  • Celeste B. Burness
  • Emma D. Deeks
Adis Drug Clinical Q&A

DOI: 10.1007/s40267-014-0144-2

Cite this article as:
Keating, G.M., Burness, C.B. & Deeks, E.D. Drugs Ther Perspect (2014) 30: 303. doi:10.1007/s40267-014-0144-2
  • 63 Downloads

Abstract

Oral dimethyl fumarate (Tecfidera®) is a useful addition to the therapeutic options available to treat relapsing-remitting MS (RRMS). In placebo-controlled trials in patients with RMSS, dimethyl fumarate 240 mg twice daily reduced the annualized relapse rate, the proportion of patients with MS relapse at 2 years, and magnetic resonance imaging-assessed disease activity. Dimethyl fumarate was generally well tolerated, with the most commonly occurring adverse events including flushing and gastrointestinal events. According to interim results of a long-term extension study, dimethyl fumarate provides continued efficacy for up to 4 years of treatment, with no new tolerability concerns.

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Gillian M. Keating
    • 1
  • Celeste B. Burness
    • 1
  • Emma D. Deeks
    • 1
  1. 1.SpringerAucklandNew Zealand